「整形」「美容」须签法律文件 填塞物或致癌搵命搏

 2012-08-24 04:57:00　来源: 香港成报 核心提示：香港法例对於医疗行为管理得十分严格，所有整容手術必须经由註册西医进行，由於大部分整容手術在医学角度来说都是非必要手術，为免事後争拗，医生与整容者事前必须做好沟通及共识，再签署相关法律性文件，始会进行手術。香港法例对於医疗行为管理得十分严格，所有整容手術必须经由註册西医进行，由於大部分整容手術在医学角度来说都是非必要手術，为免事後争拗，医生与整容者事前必须做好沟通及共识，再签署相关法律性文件，始会进行手術。整容手術的医学名称为「整形手術」，科目称为「整形外科」，也可称为「整复外科」，整形外科分为两个部分，包括：「整形修复」（plastic and reconstructive）及「美容」（cosmetic），目的是使用外科手術改变人的外表与功能，「整形外科」医生除了私人执业外，医管局辖下公立医院，也有开设「整形外科」。本报专题部记者龙艺祥报道「整形」是指透过外科手術改变身体外观，「整容」是指脸部整形，包括割双眼皮、垫下巴、隆鼻、嫩唇、造酒窝痘、种睫毛等，很多人误解医学上的「矫形」专科是「整容」，其实两者实属不同範畴。

 医学角度上「整容」无必要 「整容」是当事人因自己个人喜好或其他非医疗上的原因，以外科手術改变自己的外观，並非身体上的缺陷或伤残，在医学角度来说「整容」手術其实是没有必要的。「矫形」则是因为疾病、後天因素或意外导致永久的身体缺陷或伤残，可透过以外科手術补救或矫正，而这类手術在医学角度来说，通常是有需要或必须的。整容手術愈来愈普遍，但危险性亦极高，因为大部分整容手術都是把异物用手術放入体内，以改变身体形态，这些异物的物质今天可能认为是对人体无害，但假以时日，先前被认为无问题的物料可能被发现是致癌物质，整容者又要动手術把这些异物取出，回复原状，还有整容者要面对可能会出现的身体排斥反应，随时要「搵命搏」。香港和内地早前便證实了隆胸物质PAAG会致癌，有很多做了隆胸手術的女士都被逼再做手術把物料拿出来，受了皮肉之苦，又要打回原形，身心都受创。

「微整形」成本低风险较小 除了以手術或矫治方式达到改善外观的传统整形外，也有另一种新的「微整形科技」。「微整形」是不需要透过手術，即可达到改善外观或美容保养的效果，其优点为成本较低、且风险较小。

　市面上常见的「微整形」可分为以下两种：1.注射法：注射具有美容或保养效果的药剂，目的通常为减少皱纹、增加肌肤弹性等，常见的注射物包含肉毒桿菌、胶原蛋白、玻尿酸等。2.光疗法：透过光热照射，来达到除皱、淡斑的效果，常见的光疗法包括脉衝光、染料雷射、二极体雷射等。医学角度上「整容」无必要医学角度上「整容」无必要

ファイザー、日本市場の後発薬で提携

2012.8.24 05:00　米ファイザーと後発医薬品大手の米マイランは２２日、日本の後発薬事業で業務提携すると発表した。業務提携は日本市場に限り、資本提携は含まない。日本は医療費削減につながる後発薬の利用拡大が期待されており、提携を通じて日本市場で事業強化を図るのが狙い。　ファイザーがブランド力を生かして販売を、マイランは研究開発や製造を担当する。両社が現在販売している３５０種以上の後発薬を取り扱うほか、開発中の１２５種以上の商品も順次追加する方針。　日本は米国に次ぐ世界２位の製薬市場だが、後発薬では６位にとどまっている。ただ、政府が高齢化に伴い増え続ける医療費の削減に向けて新薬よりも価格が安い後発薬の利用促進を掲げており、今後の市場拡大が見込まれている。

金衛醫療收購New Horizon Capital III (新天域) 可換股票據

HONG KONG, Aug. 24, 2012 -- /PRNewswire-Asia/ -- Golden Meditech Holdings Limited ("Golden Meditech" , together with its subsidiaries collectively as the "Group" , - 801.HK; 910801.TW), a leading integrated healthcare enterprise in China, is increasing its ownership in hospital management business by acquiring the US$28,000,000 principal value Senior 5% Redeemable Convertible Notes due 2014 ("Convertible Notes") issued by its non-wholly-owned hospital management subsidiary, GM Hospital Group Limited ("GMHG") from its strategic investor, New Horizon Capital III, L.P. ("New Horizon").  In return, New Horizon will receive 279,344,444 new shares at the issue price of HK$0.9 per share ("Consideration Shares"), representing approximately 12.31% of the enlarged issued share capital.  Assuming Golden Meditech elects to convert all the Convertible Notes into new GMHG shares, Golden Meditech's shareholding in GMHG will increase to approximately 78.58%.  Pursuant to the agreement, New Horizon has undertaken not to dispose the Consideration Shares in any form within the period of 3 months from the completion of the agreement. "Economic growth has improved living standards in China and a consequent outcome of this has been the growth of the premium healthcare services sector.  With the launch of favourable policies from the government for the healthcare services industry, we believe the future prospects of China's hospital management market will be robust," said Mr. Kam Yuen, Chairman and Chief Executive Officer of Golden Meditech.  "We are glad of the opportunity to increase our stake in the hospital management subsidiary in order to accomplish our vision in this business as well as support our new hospital facility in Beijing which is expected to be operational by the end of this year.  Concurrently, bringing in New Horizon as a strategic investor has affirmed the support of investors on our strategy.  Golden Meditech is committed to building itself into a comprehensive healthcare enterprise driven by both medical devices and healthcare services businesses to create the greatest value for our shareholders."   

金衛醫療透過收購可換股票據提升醫院管理業務股權2012-08-25 16:51:18 香港2012年8月24日電 /美通社亞洲/ -- 中國領先綜合性醫療事業集團 - 金衛醫療集團有限公司（「金衛醫療」或連同其附屬公司，統稱為本「集團」，801.HK / 910801.TW）透過向戰略投資者新天域資本（「新天域」）收購其主要從事醫療管理業務的非全資附屬公司 GM Hospital Group Limited（「GMHG」）所發行本金總額為28,000,000美元於2014年到期之5厘優先可贖回可換股票據（「可換股票據」）。新天域將獲得按發行價每股代價股份0.9港元之279,344,444股新股份（「代價股份」），佔擴大已發行股本約12.31％。假設金衛醫療選擇將所有的可換股票據轉換為新GMHG股份，金衛醫療於GMHG的持股量將增加至約78.58％。根據協議，新天域承諾於完成協議日期起3個月期間內，不以任何形式處理代價股份。集團主席兼行政總裁甘源先生表示：「中國經濟發展蓬勃，國內生活水平顯著提升，因而對高品質醫療服務的需求亦隨之而起。我們相信在政府對醫療服務行業的多項利好政策推動下，中國醫院管理業務市場的前景將十分樂觀。我們很高興可以透過此次收購而增加於醫院管理業務部門的持股量，並配合預計將於今年年底投入運營的北京新醫院設施，實現我們擴展醫院管理業務的愿景。而成功引入新天域作戰略投資者，足以證明投資者認同金衛醫療的發展理念。我們長期致力於將金衛醫療打造成為一家以醫療設備和醫療服務為骨幹的醫療事業集團，竭力為股東創造最大的價值。」

關於金衛醫療集團有限公司 金衛醫療為中國領先的綜合性醫療事業集團，為推動行業發展的先行者。在過去幾年中，金衛醫療憑藉積極創新、進取的精神以及對醫療市場先機的把握能力，在醫療設備和醫療服務領域內的臍帶血幹細胞儲存及醫院管理業務均取得領導性地位。金衛醫療將繼續實踐其使命，通過有機增長和其他策略發展計劃，力爭成為中國領先醫療集團。

Silodosin可能用於..男性早洩 (Premature ejaculation) ~~

Silodosin and its potential for treating premature ejaculation: a preliminary report.

Sato Y, Tanda H, Nakajima H, Nitta T, Akagashi K, Hanzawa T, Tobe M, Haga K, Uchida K, Honma I. Source Department of Urology, Sanjukai Hospital, Sapporo, Hokkaido, Japan. ysato@sanjukai.or.jp Int J Urol. 2012 Mar;19(3):268-72. doi: 10.1111/j.1442-2042.2011.02941.x. Epub 2011 Dec 20.

Abstract Premature ejaculation is a common sexual problem, as is erectile dysfunction. We evaluated silodosin, a highly selective α1A-adrenoceptor antagonist, as a new treatment option for premature ejaculation. α1-Adrenoceptor antagonists are widely used for lower urinary tract symptoms, and clinical studies on silodosin have shown excellent clinical efficacy for lower urinary tract symptoms. However, compared with other α1-adrenoceptor antagonists, silodosin appeared to suppress ejaculation in a relatively higher percent of trial participants. This suppression of ejaculation by silodosin suggested its potential for treating premature ejaculation. Consequently, we evaluated the feasibility of off-label silodosin as a new treatment option for premature ejaculation. Eight patients suffering premature ejaculation were treated with silodosin. Silodosin (4 mg) was given 2 h before sexual intercourse. Intravaginal ejaculatory latency time, premature ejaculation profile item, clinical global impression change in premature ejaculation and systemic adverse events were recorded. Intravaginal ejaculatory latency time was significantly prolonged (from 3.4 min to 10.1 min, P = 0.003). All patients answered better (much better) or slightly better for their own premature ejaculation problem compared with pretreatment condition in the clinical global impression change. Premature ejaculation profile also significantly improved. Two (25%), three (37.5%) and seven patients (87.5%) experienced anejaculation, reduced semen volume and discomfort during orgasm, respectively. However, these problems were not of major concern for the participants. No systemic adverse effects were reported. The current results support the possible use of silodosin as a new treatment option for premature ejaculation, and suggest that a placebo controlled study assessing its clinical usefulness would be worthwhile.© 2011 The Japanese Urological Association.

治攝護腺肥大藥物 意外讓男性更性福   新頭殼 | 新頭殼 – 2012年8月23日 下午8:03. ....相關內容. .. 放大顯示.治攝護腺肥大藥物 意外讓男性更性福 ....新頭殼newtalk 2012.08.23 劉奕霆/台北報導 根據醫學統計，台灣50歲以上男性每2人就有1人可能患有攝護腺肥大，因此在醫學上治療的藥物也不斷進步，新店慈濟醫院外科部主任楊緒棣教授今(23)日舉行記者會指出，根據他的研究，攝護腺肥大患者使用攝護腺新藥(Silodosin)後，約有3成的人在做愛時間上有明顯延長的效果，未來有可能以此研發出能夠治療早洩的新藥物。在今年8月份的泌尿科醫學會年會中，楊緒棣教授發表研究報告，指出台灣上市的攝護腺肥大新藥(Silodosin)，具有最高選擇性甲1A型阻斷劑的特性，除可改善攝護腺肥大頻尿、尿急、夜尿、殘尿等排尿症狀，也不會造成姿勢性低血壓或心律不整等，更意外發現此阻斷劑可造成男性輸精管收縮，進而無法射精，使得做愛時間有延長的效果。楊緒棣表示，目前治療攝護腺肥大仍以藥物為主，情況嚴重則以手術切除。此次在臨床上使用新藥後發現，有數位門診病患回診後表示做愛時間有延長的情況，因此進一步調查。在調查過程中，發現26位患有攝護腺肥大且仍有性生活者，有3成病患做愛時間變長，其中符合早洩定義者，更有近7成延長做愛時間。而攝護腺肥大患者使用此藥後平均做愛時間從5分鐘增加為6.8分鐘，符合早洩定義者平均做愛時間也從1.3分鐘增加為3分鐘，合計約有97%的病人射精功能產生改變。楊緒棣說，在日本去年的研究中，年輕早洩男性服用後，約7成5的人做愛時間延長。台灣則是世界上首度發現中老年人使用後，會延長做愛時間這個意外好處的國家。 雖然如此，楊緒棣也提到，延長做愛時間並不代表絕對有益，在門診病患中就有3位60歲以上的患者，因為做愛時間長達30分鐘甚至更久，被太太要求停藥。楊緒棣表示，每個人對性的滿意度皆不同，在使用藥物前仍要仔細考慮。

流感藥: Inavir® ( Dry Powder Inhaler). :approved for sale in Japan

Inavir® is the first drug of a new class of long acting neuraminidase inhibitors (LANIs) to address the limitation of the current products, which require daily or more frequent dosing. The new class provides the opportunity to medicate patients on a "one and done" basis and offers a number of potential benefits. These include that the patient is more likely to use the product properly and as intended and also offers a reduced cost of storage and transport per course, where the product is intended to be stockpiled. Inavir® is Daiichi Sankyo's registered brand for laninamivir octanoate, also previously known as CS-8958. Inavir® is delivered via a Dry Powder Inhaler. Inavir® is not a vaccine.

Neuraminidase inhibitors Neuraminidase is essential for the replication of all influenza viruses.  It is an enzyme which allows new viruses to be released from the infected lung cells, further extending the infection.  Neuraminidase inhibitors block this activity, preventing the release and spread of new viruses.

Development and commercialization Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which Inavir® is the lead product. Under the co-ownership agreement, Daiichi Sankyo held an option to manufacture and sell laninamivir in Japan, in return for funding an extensive range of Japanese clinical trials. Biota will receive royalties on all sales of Inavir® and may qualify for additional milestone payments. Biota and Daiichi Sankyo are exploring options for development and commercialisation of laninamivir ex-Japan.

Regulatory approval Inavir® is approved for sale in Japan for the treatment of influenza in adults and children.

日本：第一三共证实“Inavir®”可预防流感病毒传染病 2012-08-23 17:54 来源：财经网 据日本媒体报道，日本第一三共公司(Daiichi Sankyo Company, Limited)为了验证抗流感病毒药物“Inavir®”(通用名称：Laninamivir Octanoate Hydrate，暂译为拉尼娜米韦辛酸酯水合物)在预防流感病毒传染病方面的效果，进行了三期临床试验。据了解，第一三共以与A(甲)型或B(乙)型流感病毒传染病患者同住的家属或共同生活者为对象，进行了随机双盲安慰剂对照试验。 2012年8月22日，第一三共发布消息称，试验结果显示，在作为预防有效性的主要评价指标流感病毒传染病的临床发病率方面，从统计学上来说，“Inavir®”使用组的发病率显著低于安慰剂使用组(即非偶然出现的差异)，证实了使用“Inavir®”具有制止流感病毒传染病发病的效果。而且，安全性方面也没有问题。另外，实际的病例数及有关效果的具体数值等详细结果预定于今后在相关学术杂志或学会上公布，具体时间待定。今后，第一三共为了在2012年内申请到“Inavir?”的制造、销售批准(适用于预防流感病毒传染病)，将不断推进各项准备工作。据了解，“Inavir®”是第一三共创制的纯日本产长效神经氨酸酶抑制剂，于2010年9月10日作为A型或B型流感病毒传染病的治疗药物取得了制造、销售批准，并于同年10月19日开始销售。(责任编辑：尹萍)来源元培产业情报)

다이이찌산쿄는 독감치료제 '이나비르'(Inavir, laninamivir)에 대해 연내 독감 예방제로 승인을 신청할 계획이라고 발표했다. 일본에서 시판되고 있는 독감치료제는 이나비르 외에 쥬가이제약의 '타미플루', 글락소스미스클라인(GSK)의 '리렌자', 시오노기제약의 '래피액타'(Rapiacta, Peramivir)가 있는데, 이 가운데 타미플루와 리렌자는 예방적응증을 이미 취득했다.  다이이찌산쿄에 따르면 예방적응증으로 실시해 온 3상 임상시험에서는 A형이나 B형 독감바이러스 감염환자와 동거인, 공동생활자를 이나비르 투여그룹과 위약 그룹으로 나눠 비교했다. 그 결과, 독감 발병률은 이나비르 투여그룹이 위약그룹에 비해 통계학적으로 유의하게 낮은 한편, 안전성 문제도 나타나지 않은 것으로 확인됐다. 이나비르는 A형과 B형 독감에 효과가 있는 성인과 소아용 흡입제. 타미플루가 하루 2회(성인) 5일간 복용할 필요가 있는 반면, 이나비르는 1회 흡입으로 효과를 보이는 특징이 있다.